Setting Realistic Weight Loss Goals on a GLP-1

The number on the patient's first appointment sheet was 28 kilograms. That was the figure they had calculated as the gap between their current weight and what they thought of as their "real" weight — the weight they had been at thirty, before the pregnancies, before the desk job, before the slow climb that had ended at the current number on the scale. The number was specific, the timeline was vague, and the entire frame of the conversation was about how quickly the medication would close the gap.

This frame is so common that endocrinology clinics have learned to gently redirect it within the first appointment. Not because the patient is wrong to want what they want, but because the science of GLP-1-mediated weight loss doesn't fit neatly into the gap-to-be-closed mental model that years of dieting culture have trained most people to bring to the conversation.

What the trial averages actually represent

STEP 1, published in the New England Journal of Medicine in 2021 with John Wilding as lead author, randomised 1,961 adults with obesity to weekly subcutaneous semaglutide 2.4mg or placebo for 68 weeks, alongside lifestyle intervention in both arms. The semaglutide group lost an average of 14.9% of baseline body weight. The placebo group lost 2.4%. The difference, roughly 12.5 percentage points, was the headline result.

SURMOUNT-1, published in the NEJM in 2022 with Ania Jastreboff as lead author, ran a comparable protocol with tirzepatide and reported an average loss of 20.9% at the highest dose (15mg weekly) over 72 weeks. The placebo group lost about 3.1%. The mean weight loss numbers are now widely quoted in clinical settings and patient marketing.

What gets quoted less often is the variance behind the means. STEP 1 reported that 32% of participants on semaglutide lost at least 20% of body weight; 14% lost at least 25%. SURMOUNT-1 reported even wider tails — 36% of participants on the 15mg tirzepatide dose lost at least 25%; 17% lost at least 30%. At the other end, roughly 14% of semaglutide participants and 9% of tirzepatide participants didn't reach the 5% threshold typically considered clinically meaningful for obesity treatment. The mean does not represent a typical outcome. It represents the centre of a wide distribution.

The clinical milestones that actually matter

The obesity medicine literature has converged on a set of weight-loss percentages that map to specific clinical outcomes. They are worth knowing because they reframe what success looks like across a range of starting points.

5% body weight loss is the threshold associated with improvements in blood pressure, lipid profiles, and glycemic control sufficient to reduce cardiovascular risk markers in most patients. The 2013 American College of Cardiology / American Heart Association / Obesity Society guidelines on overweight and obesity in adults treat 5% as the minimum clinically meaningful endpoint. For a patient starting at 100 kilograms, this is 5 kilograms — modest in scale terms, substantial in metabolic terms.

10% body weight loss tends to produce more pronounced metabolic improvements: type 2 diabetes remission in a meaningful fraction of patients, sleep apnea severity reductions, joint pain relief, fatty liver disease regression in many cases. The DiRECT trial run by Roy Taylor and Mike Lean at Newcastle showed that 10-to-15% weight loss in early type 2 diabetes produced disease remission in roughly half of participants. This threshold is what most clinicians would describe as "the level at which everything starts getting noticeably better."

15% body weight loss approaches what was historically only achievable through bariatric surgery for most patients. STEP 1's mean of 14.9% sits at this threshold. The metabolic improvements at this level are substantial and often include disease remissions and meaningful improvements in measures patients care about more than markers — energy, mobility, sleep quality, food relationship.

20% and above is the SURMOUNT-1 territory and approaches the average outcomes of sleeve gastrectomy. These losses produce changes that are visible to patients in essentially every domain — clothing size, joint health, sleep, mood, daily function. They also typically require the higher tirzepatide doses or sustained semaglutide at maximum dose, and they take 12-to-18 months to fully develop.

Why a 5% loss is genuinely worth celebrating

The cultural framing of weight loss tends to dismiss 5% as a token result — the kind of number a patient apologises for at follow-up. The clinical framing treats 5% as the floor above which meaningful health benefits begin to accrue. A patient who loses 5% in the first six months of GLP-1 therapy and maintains it has produced a result that, on average, reduces their cardiovascular risk and improves their metabolic profile. Whether the patient feels the loss is "enough" is a different question — and one worth examining, because the answer is often shaped more by dieting culture than by health outcomes.

The trajectory most patients actually follow

Weight loss on GLP-1 medications doesn't follow a linear path. The typical pattern across STEP and SURMOUNT trials looks roughly like this:

Weeks 0-to-16 (titration phase): Modest weight loss as doses are escalated. Most patients lose 2-to-6% of body weight during titration. Side effects are most pronounced; appetite suppression becomes increasingly noticeable.

Months 4-to-12: The most rapid loss phase. Patients typically lose 1-to-2% of body weight per month at maintenance dose. This is the period in which the cumulative loss moves from "noticeable" to "substantial."

Months 12-to-18: Loss continues but slows. Most patients approach their individual nadir somewhere in this window. The rate of loss decreases as the body settles into a new energy balance equilibrium.

Month 18 onward: Weight tends to stabilise, with some patients continuing to lose modestly and others holding steady. The STEP 5 trial (Garvey 2022, 104-week data) showed that maintained semaglutide therapy preserved weight loss through year two, with modest additional loss in some patients.

This trajectory is not a failure mode when it flattens. The plateau at the individual nadir is the new defended range. Weight loss plateaus on semaglutide are an expected phase of treatment, not a sign that the medication has stopped working.

The body composition question

The scale measures total weight. What patients usually care about — and what clinical outcomes track — is body composition: how much of the loss is fat and how much is lean tissue. Olof Linge's 2024 MRI sub-study of STEP 1 patients found that roughly 40% of total weight loss came from lean tissue. This proportion is consistent with what most large weight losses through any intervention produce, but it has implications for goal-setting that scale-only thinking misses.

A patient who loses 15% of body weight, with active resistance training and adequate protein, will end up with a different body composition than a patient who loses 15% sedentary on the minimum-protein default diet. Both numbers look identical on the scale. The downstream metabolic, strength, and aging trajectories differ substantially. Exercise on GLP-1 medications, particularly resistance training, is the lever that shifts the composition ratio toward more fat and less lean tissue lost.

For some patients, this is the more useful goal than a target scale number. The scale will land where it lands. What composition the loss is made of is partly under direct control.

The case against endpoint thinking

The most common framing patients bring to GLP-1 treatment is endpoint-oriented: a goal weight, a target number, a date by which the gap will be closed. The treatment doesn't fit this frame well because obesity is now formally classified as a chronic disease, and the medication is now formally a long-term management tool rather than a temporary intervention. STEP 4 (Wadden 2021) and SURMOUNT-4 (Aronne 2024) both demonstrated that discontinuation produces substantial weight regain — roughly two-thirds of the loss returns within a year off medication in the average patient.

This changes what a reasonable goal looks like. The useful question is not "what weight will I reach by month 12?" but "what weight can I sustainably maintain, on what dose, for how long?" For many patients, the answer is a weight 15-to-20% below the starting point, maintained on a continued maintenance dose, with periodic reassessment of dose and goals. GLP-1 maintenance dosing and the chronic-disease framing of obesity are more useful structures for long-term thinking than the dieting-era goal weight number.

What "ideal weight" calculations get wrong

BMI-derived "ideal weight" ranges were developed from insurance actuarial tables and population averages. They are useful for epidemiology and clinical screening; they are not useful as personal targets. A patient starting at BMI 38 who lands at BMI 30 has typically achieved substantial metabolic improvement, dramatic quality-of-life gains, and a sustainable maintenance position — even though BMI 30 is still classified as obesity. The improvement is real. The remaining BMI category label is largely a statistical artifact.

Patients who orient their goals around landing in the "normal" BMI range often find themselves chasing a number that the biology resists. The defended weight range may simply not extend that low for them. The medication will produce what it produces; the body composition gains compound over time; the metabolic improvements accumulate. Holding out for a particular BMI number can mean discounting outcomes that are genuinely good.

The honest version of the conversation

For most patients on a GLP-1, a reasonable expectation looks something like this: 12-to-20% body weight loss over 12-to-18 months, with substantial improvements in metabolic markers and quality-of-life measures along the way, requiring continued treatment at a maintenance dose to preserve the result. Some patients will exceed this range substantially. Some will fall short. The medication is more effective than any prior pharmacological option, but it is not a precision tool that delivers a specific number to a specific patient on demand.

What helps most patients is replacing the endpoint frame with a trajectory frame. The relevant questions are about direction, sustainability, and the metabolic and quality-of-life changes the loss is producing. The number on the scale at month 12 is one data point in a multi-year process, not the verdict on whether the treatment worked.

Key takeaways

• STEP 1 averaged 14.9% body weight loss on semaglutide; SURMOUNT-1 averaged 20.9% on tirzepatide 15mg — but the individual range is wide, with substantial fractions of patients above and below the mean.
• Clinical milestones: 5% loss produces meaningful metabolic improvements; 10% produces disease remissions for many; 15% approaches historical bariatric surgery outcomes; 20%+ matches sleeve gastrectomy averages.
• Weight loss follows a non-linear trajectory: slow during titration, fastest in months 4-to-12, plateauing in months 12-to-18 at an individual nadir that represents the new defended range.
• Roughly 40% of weight lost on GLP-1 therapy comes from lean tissue (Linge 2024) — body composition matters as much as scale weight, and resistance training plus protein shift the ratio.
• STEP 4 and SURMOUNT-4 demonstrated substantial regain after discontinuation, which makes endpoint-oriented thinking less useful than sustained-management thinking.
• BMI-derived "ideal weight" targets are statistical artifacts rather than personal goals — meaningful metabolic improvement frequently happens well above the "normal" BMI range.